Taro Pharmaceuticals recalls epilepsy drug

Taro Pharmaceuticals, a Hawthorne, N.Y.-based drugmaker, is recalling one lot of its drug, Lamotrigine, designed to treat epilepsy and bipolar disorder, after discovering it was cross-contaminated with a small amount of another drug substance. 

The drugmaker said Jan. 10 it discovered the lot contained a small amount of Enalapril Maleate, a drug substance used to manufacture another drug at the same facility. Enalapril Maleate is used to treat congestive heart failure and hypertension. 

Chronic exposure to Enalapril Maleate increases the risk of birth defects in a developing fetus. 

Taro has not received any reports of adverse events related to the recall. 

Consumers with the affected lot should return the Lamotrigine tablets to their pharmacy. Retailers, pharmacies and distributors should stop distributing or dispensing the affected product and return it to Taro. 

Read the full news release here

More articles on pharmacy:
GAO report hits lax oversight of 340B drug program
Venture capitalist launches company to bring drug prices down
AMAG Pharmaceuticals replacing CEO, cutting 2 drugs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers